Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota

被引：222

作者：

Cui, Yizhe ^{[1
]}

Wang, Qiuju ^{[1
]}

Chang, Renxu ^{[1
]}

Zhou, Xiaocui ^{[2
]}

Xu, Chuang ^{[1
]}

机构：

[1] Heilongjiang Bayi Agr Univ, Coll Anim Sci & Vet Med, 2 Xinyang Rd, Daqing 163319, Heilongjiang, Peoples R China

[2] China Anim Hlth & Epidemiol Ctr, Lab Zoonosis, Qingdao 266000, Shandong, Peoples R China

来源：

JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY | 2019年 / 67卷 / 10期

基金：

国家重点研发计划; 中国博士后科学基金;

关键词：

barrier function; intestinal microflora; gut-liver axis; oxidative stress; NAFLD; ANTIBIOTIC-ASSOCIATED DIARRHEA; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; DOUBLE-BLIND; NONALCOHOLIC STEATOHEPATITIS; BACTERIAL OVERGROWTH; BILE-ACIDS; PROBIOTICS; HOST; PERMEABILITY;

D O I：

10.1021/acs.jafc.9b00080

中图分类号：

S [农业科学];

学科分类号：

082806 [农业信息与电气工程];

摘要：

Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress liver injury that is closely related to obesity, insulin resistance, type 2 diabetes, atherosclerosis, and metabolic syndrome. The pathological features are diffuse hepatic vesicular steatosis, including non-alcoholic steatohepatitis, liver fibrosis, and even liver cancer. A variety of pathological outcomes cause serious harm to human health. At present, an increasing number of researchers are investigating the pathogenesis of NAFLD from the perspective of changes in the function of the intestinal barrier. The physical, chemical, immunological, and microbiological barriers in the intestinal tract constitute the complete intestinal barrier, which plays an important defensive role against the invasion of harmful substances from the intestines. Protecting the function of the intestinal barrier is a new way to treat NAFLD and its related diseases. In this perspective, we summarized the current knowledge of the role of the intestinal barrier in NAFLD.

引用

页码：2754 / 2762

页数：9

共 103 条

[1]

Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial [J].